MPNs

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

Ashwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.

Phase 3 research is underway to explore the efficacy and safety of selinexor plus ruxolitinib for the treatment of myelofibrosis in adults.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

Joseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.

Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.

Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.

After positive results from the phase 1/2 KRT-232-109 study, the phase 3 BOREAS-2 study will further evaluate the combination of navtemadlin and ruxolitinib in patients with myelofibrosis.

Post-hoc analysis results showed a reduction in spleen volume of 35% with ruxolitinib in patients with myelofibrosis.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.

In the second part of a live discussion on treating patients with myelofibrosis, Jonathan Abbas, MD, led a talk on the impact of ruxolitinib for these patients and where physicians stand with the use of fedratinib.

Ropeginterferon alfa-2b-njft was added to the NCCN guidelines and granted category 2A status for the treatment of polycythemia vera.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed the use of JAK inhibitors for treatment of patients with primary myelofibrosis.

Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial of momelotinib, a JAK1/JAK2 inhibitor that is being investigated specifically for the treatment of anemic patients with myelofibrosis.

In an interview, Ruben Mesa, MD, discussed the currently available JAK inhibitors for patients with myelofibrosis, and what is in store for the field.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ashwin Kishtagari, MD, discussed important findings on treating patients with high-risk myelofibrosis.

Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed data on therapies for a patient with polycythemia vera who did not adequately respond to hydroxyurea.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.

Andrew Kuykendall, MD, discusses recent approvals seen for patients with myeloproliferative neoplasms.